Daily Digest

The Valve Wire

Tuesday, May 19, 2026

Executive Summary

Today's biggest story is industrial, not clinical: Boston Scientific is making a $1.5 billion structural-heart wager on TAVR start-up MiRus, with an option to acquire the business outright for another $3B — a dramatic re-entry into the transcatheter aortic valve market after exiting the Lotus program in 2020. On the clinical front, a 2,929-patient EuroTR analysis shows that prior cardiac surgery materially worsens tricuspid TEER outcomes, and a 1,597-patient Chinese TAVR cohort quantifies the survival cost of bailout valve-in-valve. A 467-patient Taiwan study suggests national TAVI reimbursement expanded access to higher-risk patients without compromising mortality — a useful data point as US payers weigh coverage in younger and more complex populations.

For clinicians: today's literature triangulates around a single uncomfortable theme — patient selection and procedural complexity continue to define the gap between trial outcomes and real-world results. The EuroTR PCS analysis (Grassini et al.) is particularly important because TRILUMINATE and Tri.Fr excluded or under-enrolled redo patients, yet redo physiology is precisely what drives referrals to TEER in clinical practice. Meanwhile, Boston Scientific's MiRus deal — coupled with a $2B accelerated buyback — signals that industry capital is flowing toward TAVR competition even as Edwards' stock has drifted -4% over six months and Medtronic has shed -22% amid its cardiovascular realignment.

Today's Key Findings

EuroTR T-TEER + prior cardiac surgery (n=2,929): PCS patients had higher residual TR ≥3+ at discharge (OR 1.41), worse 2-year mortality (HR 1.25), and a higher death/HFH composite (HR 1.24). Functional improvement was preserved.
Bailout valve-in-valve TAVR (n=1,597, 48% BAV): Required in 6.2% overall; associated with 3-fold higher 30-day mortality (HR 3.09), though mid-term survival converged.
Late MI after self-expanding TAVR: Case series of 3 patients presenting with STEMI 10–50 months post-TAVR with abrupt 100% occlusion and no atherosclerosis — hypothesis-generating for delayed embolization mechanisms.
[NOTABLE] Boston Scientific–MiRus deal: $1.5B investment + $3B acquisition option for a nickel-free balloon-expandable TAVR platform. Re-shapes the competitive map.
Taiwan NHI reimbursement analysis (n=467): Coverage expansion shifted TAVI toward higher-risk patients (median STS 5.9% → 7.2%) with no mortality penalty and reduced HF readmission.

Aortic Valve (TAVR/TAVI)

Zhang and colleagues retrospectively analyzed 1,597 TAVR procedures at a high-volume Chinese center (48.3% bicuspid) to characterize bailout valve-in-valve TAVR — performed for significant residual AR or valve embolization. Bailout ViV was required in 6.2% of cases (slightly higher in BAV at 6.87% vs 5.57% TAV). Predictors were anatomically intuitive: larger annulus perimeter, lower calcification volume, non-repositionable self-expanding valves, and the operator learning curve. After inverse probability weighting, bailout ViV carried a 3-fold higher 30-day all-cause mortality (HR 3.09) and cardiovascular mortality (HR 3.49), though mid-term survival was comparable. Editorial note: the high BAV proportion in this cohort reflects practice patterns outside the major RCTs. Both ACC/AHA and ESC continue to rate TAVR for BAV as Class IIb, and findings like these — where 1 in 15 BAV patients needs a rescue second valve — reinforce why guideline caution is appropriate despite enthusiasm from registry data.

Saad et al. describe three patients presenting with STEMI 10 to 50 months after self-expanding TAVR, all with angiographically normal pre-TAVR coronaries and abrupt 100% occlusions requiring aspiration thrombectomy. The mechanism — possibly late embolization of calcific or thrombotic material — remains speculative, but the cases sharpen ongoing concerns about the long shadow of leaflet thrombosis and subclinical valve thrombus, particularly with supra-annular self-expanding designs. For the field's enthusiasm about lifetime management in younger patients, episodes like these are reminders that we still do not fully understand late thromboembolic risk.

Wang and colleagues compared 467 TAVI patients before and after Taiwan's February 2021 NHI reimbursement (258 pre, 209 post). As expected, reimbursement shifted the population toward higher risk (median STS 5.9 → 7.2%, dialysis prevalence 7.6 → 17.7%, ViV-TAVI 2.7 → 8.4%). Despite this, hospital length of stay fell from 12 to 7 days, 30-day AKI declined, and 1-year HF readmission dropped from 8.1% to 2.9%. One-year mortality was unchanged. The findings argue that reimbursement-driven access expansion need not compromise outcomes when paired with operator experience — a relevant data point for US CMS coverage debates.

Flather and Shibata publish an editorial in Heart revisiting TAVR in low-to-intermediate risk patients — a fitting companion to the ESC 2025 decision to lower the TAVR-preferred threshold to age ≥70. The piece raises familiar but unresolved questions: durability beyond 10 years, the cost of pacemaker dependence, and whether trial selection bias has inflated TAVR's apparent equipoise with surgery. The voices of Badhwar, Chikwe, Mehaffey, and Kaul on indication creep remain salient here.

From the conference circuit, TCTMD's "Structural Heart Revolution" series and AIIMS reporting its first TAVI procedure remind us that this technology continues to diffuse globally — but also that quality and outcomes data from emerging programs deserve scrutiny rather than celebration.

Mitral Valve (MitraClip, PASCAL, TMVR)

Torres and colleagues publish a narrative review in Cureus synthesizing the SMR TEER evidence base — COAPT, MITRA-FR, RESHAPE-HF2, and MATTERHORN. The review reinforces the now-conventional resolution of the COAPT/MITRA-FR discrepancy via the disproportionate MR framework, and acknowledges emerging roles for PASCAL and TMVR. It is a useful synthesis but adds no new data; readers should weight it accordingly. The clinically relevant editorial point remains: ESC 2025 has elevated TEER for ventricular SMR to Class I, LOE A, while ACC/AHA 2020 holds at Class IIa — a meaningful transatlantic divergence that will likely persist until the next ACC/AHA update.

No major new TMVR readouts today, though the Medtronic Intrepid Pivotal (n=1,056 target) and InnovHeart SATURN trials continue to enroll. TMVR remains the structural heart frontier where evidence most clearly lags enthusiasm.

Tricuspid Valve (TriClip, TTVR)

[NOTABLE] Grassini and colleagues report from the EuroTR registry (NCT0630726) on 2,929 patients undergoing tricuspid TEER between 2016 and 2024, of whom 27.2% had prior cardiac surgery (PCS). This is the largest analysis to date of T-TEER outcomes in this high-risk subgroup. Despite comparable baseline TR severity, PCS patients had significantly worse residual TR at discharge and follow-up (PCS independently predicted residual TR ≥3+: OR 1.41, p=0.01), higher 2-year all-cause mortality (HR 1.25, p=0.02), and a higher composite of death or HF hospitalization (HR 1.24, p=0.01). Notably, functional improvement (≥1-class NYHA reduction) was preserved (66% PCS vs 60% non-PCS, p=0.15). Editorial significance: ESC 2025 elevated transcatheter TV treatment to Class IIa largely on TRILUMINATE, Tri.Fr, and TRISCEND II — but these trials did not stratify outcomes by surgical history, and redo patients are a substantial proportion of real-world referrals. The EuroTR data suggest the Class IIa recommendation may overstate benefit for PCS patients, who comprise a clinically important group with isolated tricuspid disease late after left-sided surgery. Heart Teams should be appropriately cautious when extrapolating trial efficacy to this population.

The AHA Journals report on early RV reverse remodeling after transcatheter tricuspid valve replacement adds further evidence to the mechanistic case for TTVR — though the longer-term consequences of pacemaker dependence (15.9% in the recent STS/ACC registry analysis) and bleeding need to be weighed alongside symptomatic and structural improvements.

The pipeline continues to broaden: inQB8 MonarQ (TTVR, n=50), CroiValve DUO coaptation device (EFS, n=15), and the new TriClip post-market study (n=1,000 enrolling by invitation) are all active. Whether transcatheter tricuspid therapy ultimately delivers hard outcome benefits beyond QoL — and which device platform best serves which patient anatomy — remain open questions.

Surgical vs. Transcatheter Comparisons

Two ongoing trials deserve attention today. The DEDICATE-DZHK6 trial (n=1,414) — the investigator-initiated randomized comparison of TAVI vs SAVR in low-to-intermediate-risk patients in Germany — remains active in follow-up. Its 1-year results (death + stroke 5.4% TAVI vs 10.0% SAVR) heavily influenced ESC 2025's age threshold shift, but longer follow-up will be decisive. The Cedars-Sinai TAVR vs SAVR in Severe Bicuspid AS trial (n=1,200) is not yet recruiting but represents a critically needed RCT for the population most poorly served by current evidence. Until those data mature, the ESC's age ≥70 TAVR-preferred recommendation rests on extrapolation from tricuspid AV cohorts.

The REVALVE trial from Leeds (n=550) is investigating Redo-TAVI vs surgical explantation vs conservative management — a sorely needed comparison given that TAVR explant carries 12–17% mortality and most patients (84%) currently receive Redo-TAVI by default rather than by evidence.

Preprint Highlights

Today's biorxiv preprint (Muleta et al., breastmilk antibody isotypes and neonatal rotavirus) is outside our scope. No relevant valve preprints today.

Device & Technology

EmStop announced initiation of the CAPTURE-2 IDE trial of its novel cerebral embolic protection device — adding to a competitive space currently dominated by Sentinel. Whether next-generation EPDs will finally demonstrate the stroke reduction that has eluded prior trials (PROTECTED TAVR was neutral on the primary endpoint) remains the central question for the field.

The MiRus platform at the center of today's Boston Scientific deal is described as a nickel-free balloon-expandable TAVR valve using a molybdenum-rhenium (MoRe) alloy frame — a notable materials science angle, given that ~10–15% of patients have nickel sensitivity and the long-term immunologic implications of bioprosthetic frame composition are poorly characterized.

Industry & Market

[NOTABLE] Boston Scientific committed $1.5 billion to MiRus, an Atlanta-based developer of a nickel-free balloon-expandable TAVR system, with an additional $3 billion option to acquire the business outright. The transaction is paired with a $2 billion accelerated share repurchase. The deal marks BSX's de facto re-entry into the TAVR market after the 2020 wind-down of its Lotus Edge program. Strategically this targets a $7B+ global TAVR market currently dominated by Edwards (SAPIEN) and Medtronic (Evolut). The competitive implications for Edwards in particular are meaningful: a third major US player with a differentiated balloon-expandable platform could pressure pricing and force device innovation, though MiRus must still complete pivotal trials before commercial impact materializes. BSX shares rose 6.15% on the news.

Meanwhile, Medtronic's cardiovascular realignment — with facility closures and stock pressure — adds context to the competitive dynamic. The structural heart segment is in active reshuffling, and the next 18–24 months will likely see consolidation among smaller valve players (Anteris, JenaValve, Meril, J Valve).

Financial Analysis

The dominant financial story is the Boston Scientific–MiRus transaction, which simultaneously signals confidence in TAVR's long-term growth (the global TAVI market is projected at ~$7B and expanding) and creates structural risk for incumbents. The accompanying $2B accelerated share buyback suggests management views BSX shares — down 42% over six months from a 52-week high of $109.50 to today's $55.92 — as significantly undervalued, even after factoring in the dilution risk of a potential $4.5B aggregate MiRus outlay.

For Edwards Lifesciences, the news is unambiguously a longer-term competitive headwind, though the stock's modest -4.2% six-month performance suggests the market remains relatively sanguine about TAVR franchise durability. Recent insider selling — multiple Edwards executives disposed of shares over $1.4M cumulatively this week — does not appear coordinated but bears monitoring. Edwards is also navigating scrutiny over double-digit executive pay raises at a time when the broader medtech sector faces tariff and reimbursement pressures.

Medtronic's -22% six-month performance reflects broader cardiovascular franchise challenges that go beyond valves — diabetes, regulatory issues, and execution concerns are all factors. The forward P/E of 12.75 increasingly looks like a value trap or a turnaround opportunity depending on one's view of CEO Geoff Martha's strategic realignment.

Anteris (AVR.AX) continues to outperform on the strength of its DurAVR THV platform development, up 91% over six months — though as a sub-$1B market-cap pre-revenue company, it remains a binary bet on regulatory milestones.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $82.39 (+1.24%) | 6-mo: -4.22%
Market cap: $47.4B | P/E (trailing/forward): 44.5 / 24.5 | Beta: 0.87
52-week range: $72.30 – $87.89
Analyst target: $97.15 (range $84–$110, 27 analysts) | Consensus: Buy
Next earnings: 2026-07-23 (EPS est $0.74, Rev est $1.70B)
Commentary: Modest gain today but the MiRus deal looms as a longer-term competitive overhang for SAPIEN. Insider selling activity (Bobo, Lippis, others) totaling >$1.4M this week is worth monitoring, though appears to be planned dispositions. EARLY TAVR and ESC's ≥70 threshold remain bullish tailwinds. PASCAL TR and SAPIEN M3 TMVR pipeline diversifies away from pure TAVR dependence.

Medtronic (MDT)

Close: $77.32 (+1.54%) | 6-mo: -21.74%
Market cap: $99.3B | P/E (trailing/forward): 21.6 / 12.75 | Beta: 0.63
52-week range: $74.40 – $106.33
Analyst target: $108.00 (range $90–$121, 25 analysts) | Consensus: Buy
Next earnings: 2026-06-03 (EPS est $1.55, Rev est $9.62B)
Commentary: Sustained underperformance reflects cardiovascular realignment challenges and franchise execution concerns. Evolut FX+ remains a strong product, and Intrepid TMVR pivotal continues to enroll. Earnings in two weeks will be a key catalyst.

Abbott (ABT)

Close: $87.91 (+4.07%) | 6-mo: -29.52%
Market cap: $153.1B | P/E (trailing/forward): 24.6 / 14.5 | Beta: 0.65
52-week range: $81.97 – $139.06
Analyst target: $118.64 (range $92–$143, 25 analysts) | Consensus: Buy
Next earnings: 2026-07-16 (EPS est $1.28, Rev est $12.53B)
Commentary: Strong daily bounce despite a difficult 6-month period. TriClip remains a key structural heart growth driver; today's EuroTR PCS analysis is a reminder that real-world TEER outcomes are nuanced by patient selection. MitraClip continues to benefit from RESHAPE-HF2 momentum and the ESC Class I upgrade.

Boston Scientific (BSX)

Close: $55.92 (+6.15%) | 6-mo: -42.36%
Market cap: $83.1B | P/E (trailing/forward): 23.4 / 14.87 | Beta: 0.62
52-week range: $52.52 – $109.50
Analyst target: $83.44 (range $60–$106, 32 analysts) | Consensus: Strong Buy
Next earnings: 2026-07-29 (EPS est $0.83, Rev est $5.40B)
Commentary: The MiRus announcement and $2B accelerated buyback drove today's 6.15% gain, but the stock remains down 42% over six months from highs. The MiRus bet is a credible structural heart play and could re-rate the franchise if TAVR pivotal data are positive. Watchitems remain pivotal trial timing and execution.

Anteris Technologies (AVR.AX)

Close: A$10.40 (+5.69%) | 6-mo: +91.18%
Market cap: A$1.0B | Forward P/E: -4.77 | Beta: 0.59
52-week range: A$4.68 – A$10.40
Analyst target: A$13.00 (1 analyst)
Commentary: New 52-week high. DurAVR THV development continues to generate enthusiasm based on single-piece bovine pericardial design and laminar flow characteristics. Remains a high-risk speculative position pending pivotal trial design and regulatory pathway.

Market outlook: The Boston Scientific–MiRus deal crystallizes a thesis we have been articulating: structural heart is now mature enough to attract major M&A but immature enough that new entrants can still credibly challenge incumbents. The combination of guideline expansion (ESC 2025 TAVR ≥70, TEER Class I, transcatheter TR Class IIa) and demographic tailwinds supports a multi-decade growth runway, but valuations are increasingly differentiated by pipeline breadth versus pure-play exposure. Edwards' valuation premium relative to peers is becoming harder to justify if a credible third TAVR competitor emerges.

Clinical Trial Updates

Aortic Valve

NCT03112980 — Randomized Trial of TAVI vs SAVR in Severe AS at Low-Intermediate Risk (DEDICATE-DZHK6) | Active, not recruiting | n=1,414 | Univ. Hamburg-Eppendorf
[LANDMARK] NCT02701283 — Evolut Low Risk (long-term follow-up) | Active, not recruiting | n=2,223 | Medtronic
NCT07413965 — TAVR vs SAVR in Severe Bicuspid AS | Not yet recruiting | n=1,200 | Cedars-Sinai — critically needed RCT for guideline-deficient population
NCT06557798 — REVALVE: Redo-TAVI for TAV Failure | Recruiting | n=550 | Leeds NHS Trust
NCT06284837 — Secondary Access Femoral vs Radial in TAVI | Recruiting | n=542 | The Alfred
NCT07591922 — Intraoperative Music Therapy in TAVR | Recruiting | n=100 | Rhode Island Hospital
NCT06077201 — Home-Based Cardiac Rehab After Transcatheter Valve Interventions | Recruiting | n=240 | Vanderbilt

Mitral Repair

[LANDMARK] NCT04198870 — REPAIR MR (MitraClip vs surgical repair in moderate-risk degenerative MR) | Active, not recruiting | n=500 | Abbott — will help define TEER role in primary MR
[LANDMARK] NCT03706833 — COAPT (long-term follow-up) | Active, not recruiting | n=1,247 | Edwards/Abbott
[LANDMARK] NCT05051033 — PRIMATY (TEER vs surgery for PMR in patients >60) | Recruiting | n=450 | Mount Sinai
NCT07578129 — PASCAL Precision-GDMT Registry | Not yet recruiting | n=50 | Ceric Sàrl

Mitral Replacement

[LANDMARK] NCT03242642 — Intrepid TMVR Pivotal | Recruiting | n=1,056 | Medtronic
NCT06414265 — SATURN Trans-Septal TMVR | Recruiting | n=30 | InnovHeart
NCT07130994 — CASSINI-US (SATURN TMVR) | Not yet recruiting | n=15 | InnovHeart

Tricuspid Repair

[LANDMARK] NCT03904147 — TRILUMINATE Pivotal (TriClip) | Active, not recruiting | n=572 | Abbott
[LANDMARK] NCT04097145 — CLASP II TR (PASCAL) | Recruiting | n=1,270 | Edwards
NCT04483089 — bRIGHT (TriClip real-world registry) | Active, not recruiting | n=511 | Abbott
NCT07586995 — TriClip Post-Market Assessment | Enrolling by invitation | n=1,000 | Abbott

Tricuspid Replacement

[LANDMARK] NCT04482062 — TRISCEND II (Evoque) | Active, not recruiting | n=864 | Edwards
NCT06611579 — MonarQ (inQB8 TTVR) | Recruiting | n=50 | inQB8 Medical
NCT05913908 — DUO Coaptation Valve EFS | Recruiting | n=15 | CroiValve

Social & Conference Highlights

TCTMD published two fellow-focused pieces this week — "The Structural Heart Revolution: Perspectives From Fellowship and Beyond" and a companion piece on LAA closure, PFO closure, and other novel structural procedures. Both reflect the broader workforce reality: structural heart now consumes a substantial fraction of interventional cardiology training capacity, even as surgical training in valve repair faces parallel pressures. The long-term implication for valve care delivery — fewer surgeons trained in complex repair, more operators trained in catheter-based therapies — deserves ongoing scrutiny from the field.

Cardiac Wire published its "State of The Transcatheter Valve" industry overview for those wanting a broader market lens.

Looking ahead: Medtronic's earnings on June 3 will be the next major catalyst for structural heart sentiment, with particular focus on Evolut volumes and Intrepid TMVR enrollment trajectory. Watch also for further fallout from the Boston Scientific–MiRus transaction — particularly whether Edwards or Medtronic respond with M&A activity of their own.

— E. Nolan Beckett, The Valve Wire

← May 15, 2026